Overview
TFX Pharma is responsible for the TFX immunomodulatory medicine and produces thymus-derived preparations. The company has over 30 years of manufacturing experience and uses calf thymus sourced from New Zealand.
Financials
Revenue history (in k)
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 130 days for 2021).
- 202506/07/2026
- 202414/08/2025
- 202327/05/2024
- 202231/07/2023
- 202122/11/2022
- 202017/02/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Trademarks
TFX Pharma holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2025.
| Mark | Protected until | |
|---|---|---|
| TFX(word) | Mar 24, 2035 |
Authorized Representatives
Manner of representation
If the management board consists of several members, the President of the Management Board independently, two members of the management board jointly, or a member of the management board jointly with a commercial proxy, is authorised to make declarations and sign on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 10 | $918,557.54 | 98.5652% | |
Others | – | $13,371.15 | 1.4348% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-08-14.
93 1090 1522 0000 0001 3705 8027
Debt
No entries in the National Debtors Register (KRZ).
Public aid
4 public aid cases recorded, with a total value of $1,428.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 13, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Wrocławia | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $49$49 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $49$49 | Prezes Zakładu Ubezpieczeń Społecznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| F1 PharmaS.A. | $272,113.66 | f1pharma.pl | ||
| Pexon Polandsp. z o.o. | $122,615.96 | pexon.pl | ||
| Bioresearch PharmaS.A. | $76,294.71 | bioresearchpharma.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-01-14 | Share capital increase (50,000.00 PLN → 3,450,000.00 PLN) | |
| 2019-06-19 | Share capital increase (25,000.00 PLN → 50,000.00 PLN) | |
| 2018-08-03 | Entered in the register |
FAQ
Last updated: 2026-07-09